medicine-news-1/providence-service-corporation-does-not-expect-california-budget-issues-to-materially-impact-its-business-in-the-state-50992-2/;msg90356

Breaking Biology Technology:Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 2 Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 3 VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2 VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3 VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4 Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2 Caliper Life Sciences Launches Living Image(R) 4.0 Software 2

[0] Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope [0] VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 [0] Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results [0] Caliper Life Sciences Launches Living Image(R) 4.0 Software

Breaking Medicine Technology:Hill-Rom Announces Appointment of James R. Giertz to Board of Directors 2 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7 Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 2 Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 3 Catholics for Choice Statement on Healthcare Reform Bill 60931 1 Catholics for Choice Statement on Healthcare Reform Bill 60931 2 Findings show nanomedicine promising for treating spinal cord injuries 10653 1 Findings show nanomedicine promising for treating spinal cord injuries 10653 2 Findings show nanomedicine promising for treating spinal cord injuries 10653 3 APHA Applauds Prevention and Wellness Provisions in House Health Reform Bill 60929 1 APHA Applauds Prevention and Wellness Provisions in House Health Reform Bill 60929 2

[0] Hill-Rom Announces Appointment of James R. Giertz to Board of Directors [0] Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology [0] Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting